TIROFIBAN HYDROCHLORIDE MONOHYDRATE

PRODUCT IDENTIFICATION
CAS NO. 144494-65-5, 151065-53-1 (Parent)
151065-53-1 (HCl)
150915-40-5 (HCl hydrate)		TIROFIBAN
EINECS NO.  
FORMULA C22H36N2O5S·HCl·H2O
MOL WT. 495.07

TOXICITY

  

H.S. CODE

 2935.00.6000
SYNONYMS Aggrastat; Tirofiban hydrochloride monohydrate;
N-(Butylsulfonyl)-4-(4-(4-piperidyl)butoxy)-L-phenylalanine monohydrochloride monohydrate; N-(Butylsulfonyl)-O-(4-(4-piperidinyl)butyl)-L-tyrosine hydrochloride hydrate;
SMILES c1c(C[C@@H](C(O)=O)NS(CCCC)(=O)=O)ccc(c1)OCCCCC1 CCNCC1.Cl.O

CLASSIFICATION

Cardiovascular agent, Fibrin modulating agent, Fibrinolytic agent, Hematologic agen, Platelet aggregation inhibitor, Sulfonamide, Piperidine

EXTRA NOTES

 a potent non-peptide, glycoprotein IIb/IIIa inhibitor. Blocks platelet aggregation and thrombus formation.
Treatment of unstable angina.
Platelet glycoprotein-IIb/IIIa receptor antagonist. 

PHYSICAL AND CHEMICAL PROPERTIES
PHYSICAL STATE

white to off-white crystalline powder

MELTING POINT

135 - 137 C

BOILING POINT

 

SPECIFIC GRAVITY  
SOLUBILITY IN WATER

 

SOLVENT SOLUBILITY  
pH  
VAPOR DENSITY

 

REFRACTIVE INDEX

  

NFPA RATINGS

 

AUTOIGNITION

 

FLASH POINT

 

STABILITY Stable under normal conditions.

EXTERNAL LINKS & GENERAL DESCRIPTION

Wikipedia Linking

Google Scholar Search

Drug Information Portal (U.S. National Library of Medicine) - Tirofiban

http://www.nejm.org/doi/
A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina

http://circ.ahajournals.org/
Tirofiban, a tyrosine derivative with a molecular weight of 495 kD, is a novel, highly selective inhibitor of fibrinogen binding to platelet GP IIb/IIIa. Preclinical and clinical studies have confirmed that tirofiban inhibits ex vivo platelet aggregation in response to a variety of agonists, including ADP, collagen, epinephrine, and thrombin. Potential advantages of such a drug include immediate onset of action, rapid reversal of antiplatelet activity after drug discontinuation, suitability for multiple repeat administrations, and high specificity for the IIb/IIIa receptor.

http://www.drugbank.ca/
Mechanism of action: Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of tirofiban.
SALES SPECIFICATION

APPEARANCE

white to off-white crystalline powder

IDENTIFICATION

passes Test

ASSAY

99.0% min
MELTING POINT

134 - 138 C
OPTICAL ROTATION

-13° ~ -16°

IMPURITY

Individual impurity: 0.5% max
Total impurity: 1.0% max

SULPHATED ASH

0.1% max
TRANSPORTATION
PACKING
 
HAZARD CLASS  
UN NO.  
PRICE INFORMATION